FY 2022 Final Results
RUA Life Sciences’ FY 2022 results included total revenues that increased by 6% on the previous year highlighting the movement beyond the pandemic of the medical device sector. After the dust has settled on the revised requirements for the 510(k) vascular graft re-submission, the way forward is now clear which we explore in the body of this note. Our forecasts have only needed modest and non-material updates for RUA’s YE 2022 financials and our valuation remains unchanged.Our financial estimates and forecasts have barely changed since RUA’s FY 2022 trading update so our group valuation remains at £121.0m or 545p per share.
Aortech International is an Intellectual Property (IP) holding company whose principal activity is exploiting the value of its IP and know-how.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.